Currently there are two HDAC6-specific inhibitors in Phase I/II clinical trials, ACY-1215 and ACY-241, but much remains to be discovered concerning how HDAC6 interacts with DNA damage response (DDR) proteins and how HDAC6 inhibition impacts tumor DDR activity. Here, HDAC6 is linked to neoplasm.